To investigate whether low-dose oral doxycycline monohydrate , a drug capable of inhibiting microglial activation , can improve or slow the deterioration of retinal function and whether it can induce regression or slow progression of diabetic retinopathy in patients with mild to moderate nonproliferative diabetic retinopathy ( NPDR ) .